3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostatic Diseases
1
Male Urogenital Diseases
1
Genital Diseases, Male
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
12
Cisplatin
5
Cetuximab
5
Paclitaxel
4
durvalumab
3
Nivolumab
3
Ipilimumab
3
Gemcitabine
3
Cyclophosphamide
3
poly ICLC
2
avelumab
2
Radiation
2
Pemetrexed
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tislelizumab
1
tirbanibulin
1
spartalizumab
1
sonidegib
1
sitravatinib
1
repotrectinib
1
pralsetinib
1
pertuzumab
1
pepinemab
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma
×
gedatolisib
×
Clear all
NCT02920450
2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2
Terminated
3 enrolled
8 charts